APA (7th ed.) Citation

JC, S., A, R., SR, F., G, P., L, M., N, T., . . . E, W. (2025). Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study. Expert opinion on biological therapy, 25(8), 913. https://doi.org/10.1080/14712598.2025.2538608

Chicago Style (17th ed.) Citation

JC, Szepietowski, et al. "Efficacy and Safety of the Ustekinumab Biosimilar, Bmab 1200, Versus Reference Ustekinumab in Moderate-to-severe Plaque Psoriasis: 28‑week Results of the Randomized, Double-blind, Phase 3 STELLAR-2 Study." Expert Opinion on Biological Therapy 25, no. 8 (2025): 913. https://doi.org/10.1080/14712598.2025.2538608.

MLA (9th ed.) Citation

JC, Szepietowski, et al. "Efficacy and Safety of the Ustekinumab Biosimilar, Bmab 1200, Versus Reference Ustekinumab in Moderate-to-severe Plaque Psoriasis: 28‑week Results of the Randomized, Double-blind, Phase 3 STELLAR-2 Study." Expert Opinion on Biological Therapy, vol. 25, no. 8, 2025, p. 913, https://doi.org/10.1080/14712598.2025.2538608.